Smith & Nephew plc (NYSE:SNN) Shares Acquired by Clark Estates Inc. NY

Clark Estates Inc. NY lifted its stake in Smith & Nephew plc (NYSE:SNN) by 16.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 800,000 shares of the medical equipment provider’s stock after buying an additional 115,000 shares during the period. Smith & Nephew comprises approximately 3.8% of Clark Estates Inc. NY’s holdings, making the stock its 5th largest holding. Clark Estates Inc. NY owned approximately 0.18% of Smith & Nephew worth $19,664,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bleakley Financial Group LLC raised its position in shares of Smith & Nephew by 3.5% during the 4th quarter. Bleakley Financial Group LLC now owns 17,704 shares of the medical equipment provider’s stock valued at $435,000 after acquiring an additional 596 shares during the last quarter. First Trust Direct Indexing L.P. raised its holdings in Smith & Nephew by 6.9% during the third quarter. First Trust Direct Indexing L.P. now owns 9,659 shares of the medical equipment provider’s stock worth $301,000 after acquiring an additional 626 shares in the last quarter. Principal Securities Inc. increased its holdings in Smith & Nephew by 87.6% during the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 691 shares during the last quarter. GAMMA Investing LLC grew its holdings in Smith & Nephew by 31.8% during the fourth quarter. GAMMA Investing LLC now owns 2,975 shares of the medical equipment provider’s stock worth $73,000 after purchasing an additional 718 shares during the period. Finally, Townsquare Capital LLC raised its stake in Smith & Nephew by 5.4% in the 3rd quarter. Townsquare Capital LLC now owns 14,759 shares of the medical equipment provider’s stock valued at $460,000 after acquiring an additional 761 shares during the period. Institutional investors and hedge funds own 25.64% of the company’s stock.

Analyst Upgrades and Downgrades

SNN has been the subject of a number of recent research reports. Canaccord Genuity Group reissued a “hold” rating and issued a $27.00 price objective on shares of Smith & Nephew in a report on Wednesday, February 26th. StockNews.com raised Smith & Nephew from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 26th. Finally, Berenberg Bank cut shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Wednesday, November 6th. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $27.00.

Smith & Nephew Price Performance

SNN opened at $29.98 on Wednesday. Smith & Nephew plc has a twelve month low of $23.65 and a twelve month high of $31.72. The firm has a 50-day moving average price of $25.57 and a 200-day moving average price of $27.20. The company has a quick ratio of 1.11, a current ratio of 2.51 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $13.11 billion, a price-to-earnings ratio of 13.88, a PEG ratio of 1.26 and a beta of 0.84.

Smith & Nephew Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Friday, March 28th will be given a dividend of $0.447 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a dividend yield of 2.5%. This is a boost from Smith & Nephew’s previous semi-annual dividend of $0.29. Smith & Nephew’s dividend payout ratio (DPR) is 41.20%.

Smith & Nephew Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.